Peritoneal Cavity Model

Mesothelial surfaces and the surrounding extracellular matrix provide the anatomical and structural context in which introduced cancer cells or tissue encounter the peritoneum. Their interactions can influence whether tumor material attaches, survives, and develops into metastatic growth. Including these components helps investigators examine implantation within a defined serosal environment rather than studying cancer cells independently of their tissue site.

Immune cells and peritoneal fluid contribute biological conditions that can alter tumor-cell survival and dissemination within the abdominal cavity. These factors help explain why tumor burden, metastatic growth, and ascites may develop differently in the peritoneum than in other experimental settings. Their inclusion supports analysis of how the local environment shapes cancer progression and treatment response.

It can connect disease progression with events occurring at a defined anatomical site, including tumor-cell survival, implantation, dissemination, and expansion within the peritoneum. Researchers can then evaluate outcomes such as tumor burden, ascites, and metastatic growth together. This combination provides a way to study peritoneal carcinomatosis as a process shaped by both cancer cells and their abdominal environment.

Common animal versions begin by introducing either tumor cells or tumor tissue into the peritoneal cavity. The introduced material then encounters mesothelial surfaces, extracellular matrix, immune cells, and peritoneal fluid. Subsequent observations can focus on implantation, dissemination, metastatic growth, tumor burden, ascites, or responses to treatment, depending on the experimental question.

Key outcomes include the extent of tumor burden, development of ascites, patterns of metastatic growth, and the ability of cancer cells to establish within the peritoneum. These measurements help characterize how disease progresses in the abdominal serosal environment. They also provide endpoints for assessing whether localized or systemic therapies alter tumor development or treatment response.

The approach is useful when investigators need to study cancers that disseminate or establish tumors within the peritoneal cavity, including ovarian, colorectal, and gastric cancer. It supports analysis of tumor biology at the relevant anatomical site and enables evaluation of both localized and systemic therapies. Results can therefore link peritoneal disease behavior with therapeutic response.